Drug Trial Radar · NCT04617028
Jaktinib Versus Hydroxycarbamide in Subjects With Intermediate-2 or High-risk Myelofibrosis
Last checked: Nov 19, 2026Latest source record: Nov 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
105
Actual
Start
Feb 5, 2021
Primary completion
Oct 18, 2023
Study completion Oct 18, 2023
Sponsor
- Lead sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,LtdIndustry
- Sponsor type
- Industry
- First posted
- Nov 5, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to determine the efficacy of Jaktinib versus Hydroxycarbamid in participants with Intermediate-2 or High-risk myelofibrosis
Conditions
- Myelofibrosis
Interventions
JaktinibDrug
Jaktinib Hydrochloride Tablets administered orally twice daily
Placebo to match HydroxycarbamideDrug
Placebo to match Hydroxycarbamide Tablets administered orally twice daily
Hydroxycarbamide TabletsDrug
Hydroxycarbamide Tablets administered orally twice daily
Placebo to match JaktinibDrug
Placebo to match Jaktinib Tablets administered orally twice daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Splenic response rate at Week 24Time frame: Week 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Medical School of Zhejiang University
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.